NASPGHAN 2025 Annual Meeting Recap – HCPLive
Okay, here’s a breakdown of the provided text, focusing on the key information and summarizing it:
Overall Topic: Updates from NASPGHAN (North american Society for Pediatric Gastroenterology, Hepatology & Nutrition) 2025, specifically regarding treatments for pediatric liver and gastrointestinal conditions.
Key Findings/Highlights:
* Tenapanor in Pediatric IBS-C: An interview with Thomas Wallach,MD,discusses the safety and tolerability of tenapanor in pediatric patients with IBS-C (Irritable Bowel syndrome with Constipation). [Link provided to the full interview].
* Odevixibat for FIC1 Deficiency (PFIC1): Odevixibat demonstrates sustained benefits in patients with FIC1 deficiency, reducing serum bile acids and improving pruritus (itching) over up to 96 weeks of treatment. This suggests a durable effect on both the biochemical and symptomatic aspects of the condition. [Link provided for more information].
* odevixibat for Alagille Syndrome: Odevixibat treatment improves long-term quality of life and sleep in patients with Alagille syndrome.
In essence,the text highlights positive results for odevixibat in two rare liver diseases (FIC1 deficiency and alagille syndrome) and provides a link to information about tenapanor for a more common condition (pediatric IBS-C).